Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Hepatology International

• Publication date

  2016-01-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12072-015-9695-0PMID 26742762
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study

  2016cited by this paper
• Quantification of portal–bridging fibrosis area more accurately reflects fibrosis stage and liver stiffness than whole fibrosis or perisinusoidal fibrosis areas in chronic hepatitis C

  2015cited by this paper
• EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis.

  2015cited by this paper
• Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography–defined subclinical cirrhosis

  2015cited by this paper
• Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

  2015cited by this paper
• P0097 : Precisely quantitating the dynamics of liver cirrhosis in a rat model

  2015cited by this paper
• Is widespread screening for hepatitis C justified?

  2015cited by this paper
• Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

  2015cited by this paper
• Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study

  2015cited by this paper
• Diagnosis of Liver Fibrosis: Present and Future

  2015cited by this paper
• Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

  2015cited by this paper
• Reversibility of hepatitis B virus cirrhosis after therapy: who and why?

  2015cited by this paper
• Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.

  2015cited by this paper
• Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis

  2015cited by this paper
• Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop

  2015cited by this paper
• Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.

  2015cited by this paper
• Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.

  2015cited by this paper
• Validation of hepatitis B virus–related hepatocellular carcinoma prediction models in the era of antiviral therapy

  2015cited by this paper
• Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?

  2015cited by this paper
• Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009

  2015cited by this paper
• Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C

  2014cited by this paper
• Image analysis of liver biopsy samples measures fibrosis and predicts clinical outcome.

  2014cited by this paper
• Hepatocellular carcinoma: clinical frontiers and perspectives

  2014cited by this paper
• qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients.

  2014cited by this paper
• Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease

  2014cited by this paper
• Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers

  2014cited by this paper
• Quantification of portal–bridging fibrosis area more accurately reflects fibrosis stage and liver stiffness than whole fibrosis or perisinusoidal fibrosis areas in chronic hepatitis C

  2014cited by this paper
• Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?

  2014cited by this paper
• Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases.

  2014cited by this paper
• Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis.

  2014cited by this paper
• Current status of fibrosis markers

  2014cited by this paper
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2014cited by this paper
• Cirrhosis Regression and Subclassification.

  2013cited by this paper
• Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

  2013cited by this paper
• A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.

  2013cited by this paper
• Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.

  2013cited by this paper
• Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis

  2013cited by this paper
• Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C

  2013cited by this paper
• Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

  2013cited by this paper
• The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.

  2013cited by this paper
• Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells

  2013cited by this paper
• A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.

  2013cited by this paper
• The global NAFLD epidemic

  2013cited by this paper
• progression to bridging fibrosis in non-alcoholic fatty liver disease over 4 years in the Nash Crn : 602

  2013cited by this paper
• Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.

  2013cited by this paper
• Quantitative histological‐hemodynamic correlations in cirrhosis

  2012cited by this paper
• HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms.

  2012cited by this paper
• Regression of fibrosis: the need for quantitative methods of assessment.

  2012cited by this paper
• The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis.

  2012cited by this paper
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cited by this paper
• Predictive scores for hepatocellular carcinoma development in chronic hepatitis B virus infection: "does one size fit all?".

  2012cited by this paper
• Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation

  2012cited by this paper
• Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

  2012cited by this paper
• Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

  2012cited by this paper
• Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C Virus 1 year after liver transplantation

  2011cited by this paper
• Biomarkers of liver fibrosis: What lies beneath the receiver operating characteristic curve?

  2011cited by this paper
• Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality

  2011cited by this paper
• Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.

  2011cited by this paper
• Human Fatty Liver Disease: Old Questions and New Insights

  2011cited by this paper
• High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe

  2011cited by this paper
• Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

  2011cited by this paper
• Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension.

  2011cited by this paper
• Excess liver‐related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care

  2011cited by this paper
• Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years

  2010cited by this paper
• Outcome of sustained virological responders with histologically advanced chronic hepatitis C

  2010cited by this paper
• Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.

  2010cited by this paper
• Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis.

  2010cited by this paper
• Liver stiffness: a novel parameter for the diagnosis of liver disease

  2010cited by this paper
• Sustained virologic response prevents the development of esophageal varices in compensated, Child‐Pugh class A hepatitis C virus–induced cirrhosis. A 12‐year prospective follow‐up study

  2010cited by this paper
• Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years

  2010cited by this paper
• The natural history of chronic hepatitis B virus infection

  2009cited by this paper
• Hepatitis B virus immunotolerant patients: need to differentiate patients with or without liver disease.

  2009cited by this paper
• Computer‐assisted image analysis of liver collagen: Relationship to Ishak scoring and hepatic venous pressure gradient

  2009cited by this paper
• Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)

  2009cited by this paper
• Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B.

  2009cited by this paper
• Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT‐C trial

  2009cited by this paper
• Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5‐year follow‐up of 150 patients

  2009cited by this paper
• Liver biopsy findings in chronic hepatitis B

  2009cited by this paper
• An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa‐2b combination therapy for chronic hepatitis C

  2009cited by this paper
• Histological subclassification of cirrhosis based on histological–haemodynamic correlation

  2008cited by this paper
• Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression

  2008cited by this paper
• Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C

  2008cited by this paper
• Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases.

  2008cited by this paper
• Histological benefits of virological response to peginterferon alfa‐2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis

  2008cited by this paper
• Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.

  2008cited by this paper
• Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT.

  2008cited by this paper
• High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels

  2008cited by this paper
• Diagnosis and quantitation of fibrosis.

  2008cited by this paper
• Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386‐patient study from Taiwan

  2007cited by this paper
• Pathology of fatty liver disease

  2007cited by this paper
• Liver stiffness measurement predicts severe portal hypertension in patients with HCV‐related cirrhosis

  2007cited by this paper
• Progression of fibrosis in advanced chronic hepatitis C: Evaluation by morphometric image analysis

  2007cited by this paper
• Liver fibrosis and chronic viral hepatitis.

  2007cited by this paper
• Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: A prospective study

  2007cited by this paper
• Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

  2006cited by this paper
• Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices.

  2006cited by this paper
• Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis.

  2006cited by this paper
• The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.

  2005cited by this paper
• Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

  2005cited by this paper
• Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens.

  2005cited by this paper

• A novel deacetylase inhibitor KLX suppresses liver fibrosis by deacetylating PPARγ through promoting ubiquitination-mediated HDAC1 degradation

  2025cites this paper
• AI Digital Pathology Using qFibrosis Shows Heterogeneity of Fibrosis Regression in Patients with Chronic Hepatitis B and C with Viral Response

  2024cites this paper
• Cellular fibronectin-targeted fluorescent aptamer probes for early detection and staging of liver fibrosis.

  2024cites this paper
• Innovative pharmacotherapy for hepatic metabolic and chronic inflammatory diseases in China

  2024cites this paper
• Curcumin blunts epithelial-mesenchymal transition of hepatocytes to alleviate hepatic fibrosis through regulating oxidative stress and autophagy

  2020cites this paper
• Quantitative evaluation of liver fibrosis based on ultrasound radio frequency signals: An animal experimental study

  2020cites this paper
• Hepatic cirrhosis according to the forensic medical autopsy data from Moscow for the period of 2007-2016

  2019cites this paper
• Pokeweed antiviral protein attenuates liver fibrosis in mice through regulating Wnt/Jnk mediated glucose metabolism

  2018cites this paper
• Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of nonadvanced liver fibrosis for chronic hepatitis B

  2018cites this paper
• Long-term effects of human amniotic membrane in a rat model of biliary fibrosis

  2017cites this paper
• Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection

  2017cites this paper
• World Journal of Hepatology

  year unknowncites this paper